Physician

Rajeev Kulkarni, MD

According to 2025 Medicare claims, Rajeev Kulkarni, MD (NPI: 1598825085) practices hematology/oncology in the Dayton-Kettering-Beavercreek, OH market, with the plurality of this provider's patient population coming from Miami, OH. This provider's primary affiliated billing organization is DAYTON PHYSICIANS, LLC (NPI: 1902844947; TIN: 203130844) and primary practice location at 45373-3837.

Kulkarni's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 621 traditional Medicare patients, billed 359,078 HCPCS/CPT codes, and received $4,072,113 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,215 prescription claims across 339 beneficiaries totaling $9,078,529 in drug costs, led by Imbruvica (Ibrutinib). 2023 DME data shows 26 claims. Open Payments data shows 127 records totaling $2,601. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,412,658 to $4,072,113. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,282,777 to $9,078,529. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	581	130,610	$1,412,658
2016	613	146,911	$1,497,230
2017	609	132,076	$1,419,605
2018	610	148,097	$1,360,679
2019	735	224,606	$2,521,583
2020	741	170,197	$2,532,718
2021	668	146,058	$2,605,048
2022	725	205,545	$3,398,009
2023	635	289,645	$4,186,147
2024	621	359,078	$4,072,113

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	246	1,068	$1,282,777
2016	250	1,022	$1,732,416
2017	255	1,055	$1,759,003
2018	291	1,228	$2,354,898
2019	312	1,488	$3,225,802
2020	327	1,968	$4,662,517
2021	302	1,899	$5,296,587
2022	357	1,873	$6,553,605
2023	343	2,052	$6,958,960
2024	339	2,215	$9,078,529

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	162	$10,711
2016	N/R	134	$5,974
2017	N/R	24	$891
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	12	$1,578
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	26	$1,014
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	98	98	$153
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	261	980	$128
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	445	1,020	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	62	63	$66
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	552	1,924	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	154	4,312	$2,415,776
Lenalidomide	Lenalidomide	87	2,436	$1,199,258
Ibrance	Palbociclib	39	1,092	$611,542
Pomalyst	Pomalidomide	26	728	$568,462
Calquence	Acalabrutinib Maleate	36	1,080	$529,261

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	127	$2,601	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rajeev Kulkarni, MD?

Tedicare shows public-source Medicare data for Rajeev Kulkarni, MD (NPI 1598825085), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rajeev Kulkarni, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rajeev Kulkarni, MD?

Rajeev Kulkarni, MD is linked to DAYTON PHYSICIANS, LLC (billing NPI 1902844947) in the available physician profile data.

Does Rajeev Kulkarni, MD have Open Payments data?

Rajeev Kulkarni, MD has 127 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.